Failure to maintain adherence to haart in a cohort of French HIV-positive injecting drug users

  • M. P. Carrieri
  • M. A. Chesney
  • B. Spire
  • A. Loundou
  • A. Sobel
  • G. Lepeu
  • J. P. Moatti


The study, carriedoutintheFrench MANIF2000 cohortofHIVpositive patients contaminated through injecting drug use, assessed the impact of patients’ sociodemographic and psychological characteristics, behaviors toward drug abuse, and antiretroviral treatment characteristics on the maintenance of adherence to HAART (highly active antiretroviral therapies). A total of 96 patients (30 men and 66 women), who were initially adherent at their first visit after HAART prescription, were considered for analysis. Among these 96 patients, 22 (22.9%) experienced adherence failure defined as a self-reported, non-adherence behavior at any visit before the 18th month of treatment. Logistic regression showed that lack of a stable relationship, active drug injection, and depression were independently associated with adherence failure. Patients’ counseling for facilitating maintenance of adherence to HAART over time should focusonpreventionofdrug use, provisionofsocial support and consider the potential impact of difficulties with treatment on psychological well-being.

Key words

adherence failure HIV depression injecting drug users (IDU) highly active antiretroviral therapies (HAART) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Altice, F., & Friedland,J. (1998). The eraofadherenceto antiretroviral therapy.Annals of Internal Medicine, 129, 503–505.PubMedGoogle Scholar
  2. Avants, S. K., Margolin, A., Warburton, L. A., Hawkins, K. A., & Shi, J. (2001). Predictors of nonadherenceto HIV-related medication regimens during methadone stabilization.American Journal of Addiction, 10, 69–78.CrossRefGoogle Scholar
  3. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D.,Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.AIDS, 14, 357–366.PubMedCrossRefGoogle Scholar
  4. Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., et al. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.AIDS, 15, 1181–1183.PubMedCrossRefGoogle Scholar
  5. Bassetti, S., Battegay, M., Furrer, H., Rickenbach, M., Flepp, M., Kaiser, L., et al. (1999). Why ishighly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.Journal of Acquired Immune Deficiency Syndromes, 21, 114–119.PubMedGoogle Scholar
  6. Calabrese, L. H. (2001). Changing patterns of morbidity and mortality in HIV disease.Cleveland Clinical Journal of Medicine, 68, 105, 9–10, 12.Google Scholar
  7. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors.AIDS, 12, F51-F58.PubMedCrossRefGoogle Scholar
  8. Carrieri, M., Cailleton, V., Le Moing, V., Spire, B., Dellamonica, P., Bouvet, E., et al. (2001). The dynamic of adherence to highly active antiretroviral therapy (HAART): Results from the French National APROCO cohort.Journal of Acquired Immune Deficiency Syndrome, 28, 232–239.Google Scholar
  9. Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., & McAuliffe, T. L. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease.Health Psychology, 19, 124–133.PubMedCrossRefGoogle Scholar
  10. Chesney, M. A., Ickovics, J., Hecht, F. M., Sikipa, G.,; & Rabkin, J. (1999). Adherence: A necessity for successful HIV combination therapy.AIDS, 13, S271-S278.PubMedCrossRefGoogle Scholar
  11. Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwicki, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committeeofthe Adult AIDS ClinicalTrials Group (AACTG).AIDS Care, 12, 255–266.PubMedCrossRefGoogle Scholar
  12. Chesney, M. A., Morin, M., & Sherr, L. (2000). Adherence to HIV combination therapy.Social Science & Medicine, 50, 1599–1605.CrossRefGoogle Scholar
  13. Clumeck, N., Goebel, F., Rozenbaum, W., Gerstoft, J., Staszewski, S., Montaner, J., et al. (2001). Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.AIDS, 15, 1517–1526.PubMedCrossRefGoogle Scholar
  14. Cook, R. L., Sereika, S. M., Hunt, S. C., Woodward, W. C., Erlen, J. A., & Conigliaro, J. (2001). Problem drinking and medication adherence among persons with HIV infection.Journal of General Internal Medicine, 16, 83–88.PubMedCrossRefGoogle Scholar
  15. Duong, M., Piroth, L., Peytavin, G., Forte, F., Kohli, E., Graypin, M., et al. (2001). Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response.Clinical Infectious Diseases, 33, 386–392.PubMedCrossRefGoogle Scholar
  16. Duran, S., Saves, M., Spire, B., Cailleton, V., Sobel, A., Carrieri, P., et al. (2001). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy.AIDS, 15, 2441–2444.PubMedCrossRefGoogle Scholar
  17. Duran, S., Solas, C., Spire, B., Carrieri, M. P., Fuzibet, J. G., Costagliola, D., et al. (2001). “Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?” A comparison between patients’ self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study.AIDS, 15, 1075–1077.PubMedCrossRefGoogle Scholar
  18. Duran, S., Spire, B., Raffi, F., Walter, V., Bouhour, D., Taurnot, J., et al. (2001). Self-reported symptoms after initiationof a protease inhibitorin HIV-infected patients and their impact on adherence to HAART.HIV Clinical Trials, 2, 38–45.PubMedCrossRefGoogle Scholar
  19. Eron, J. J., Yetzer, E. S., Ruane, P. J., Becker, S., Sawyer, G. A., Fisher, R. L., et al. (2000). Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.AIDS, 14, 671–681.PubMedCrossRefGoogle Scholar
  20. Fuhrer, R., & Rouillon, F. (1989). Laversion française de ľéchelle CES-D [Description and translation of the autoevaluation scale].Psychiatrie et Psychobiologie, 4, 163–166.Google Scholar
  21. Gifford, A. L., Bormann, J. E., Shively, M. J., Wright, B. C., Richman, D. D., & Bozzette, S. A. (2000). Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens.Journal of Acquired Immune Deficiency Syndromes, 23, 386–395.PubMedGoogle Scholar
  22. Gordillo, V., del Amo, J., Soriano, V., & Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy.AIDS, 13, 1763–1769.PubMedCrossRefGoogle Scholar
  23. Graham, N. M. (1998). Studies of antiretroviral therapy in the Multicenter AIDS Cohort Study.Journal of Acquired Immune Deficiency Syndrome &Human Retrovirology, 17, S9-S12.Google Scholar
  24. Haubrich, R. H., Little, S. J., Currier, J. S., Forthal, D. N., Kemper, C. A., Beall, G. N., et al. (1999). The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group.AIDS, 13, 1099–107PubMedCrossRefGoogle Scholar
  25. Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J., O’Shaughnessy, M. V., Schechter, M. T., et al. (1998). Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.The Journal of the American Medical Association, 279, 450–454.CrossRefGoogle Scholar
  26. House, J. (1981).Work, stress, and social support. Reading, MA: Addison-Wesley.Google Scholar
  27. Hung, C. C., Chen, M. Y., Hsieh, S. M., Sheng, W. H., & Chang, S. C. (2000). Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: A 5-year prospective study.Journal of Acquired Immune Deficiency Syndromes, 24, 378–385.PubMedGoogle Scholar
  28. Johnston-Roberts, K., & Mann, T. (2000). Barriers to antiretroviral medication adherence in HIV-infected women.AIDS Care, 12, 377–386.CrossRefGoogle Scholar
  29. Kastrissios, H., Suarez, J., Katzenstein, D., Girard, P., Sheiner, L., & Blaschke, T. (1998). Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial.AIDS, 12, 2295–2303.PubMedCrossRefGoogle Scholar
  30. Lerner, B., Gulick, R., & Dubler, N. (1998). Rethinking non-adherence: Historical perspectives on triple-drug therapy for HIV disease.Annals of Internal Medicine, 129, 573–578.PubMedGoogle Scholar
  31. Levy, R. L. (1983). Social support and compliance: A selective review and critique of treatment integrity and outcome measurement.Social Science & Medicine, 17, 1329–1338.CrossRefGoogle Scholar
  32. Liang, K.,; & Zeger, S. (1986). Longitudinal data analysis using generalized linear models.Biometrika, 73, 13–22.CrossRefGoogle Scholar
  33. Lucas,G. M., Cheever, L.W., Chaisson, R. E., & Moore, R. D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.Journal of Acquired Immune Deficiency Syndromes, 27, 251–259.PubMedGoogle Scholar
  34. Mannerheimer, S., Friedland, G., Matts, J., Chen, L., Child, C., McArthur, M., et al. (2000).Self-reported antiretroviral adherence correlates with HIV viral load and declines over time. Presented at XIIIth International AIDS conference, Durban, 2-14, July 2000. Abstract TUORB421.Google Scholar
  35. Max, B.,; & Sherer, R. (2000). Management of the adverse effects of antiretroviral therapy and medication adherence.Clinical Infectious Diseases, 30(Suppl 2), S96-S116.PubMedCrossRefGoogle Scholar
  36. Miller, L. G., & Hays, R. D. (2000). Adherence to combination antiretroviral therapy: Synthesis of the literature and clinical implications.The AIDS Reader, 10, 177–185.PubMedGoogle Scholar
  37. Moatti, J., Spire, B.,; & Duran, S. (2000). A review of socio-behavioural studies on adherence to antiretroviral treatments: Beyond biomedical models?Revue ďEpidemiologie et de Santé Publique, 48, 182–197.Google Scholar
  38. Moatti, J. P., Carrieri, M. P., Spire, B., Gastaut, J. A., Cassuto, J. P., & Moreau, J. (2000). Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.AIDS, 14, 151–155.PubMedCrossRefGoogle Scholar
  39. Molina, J. M., Ferchal, F., Rancinan, C., Raffi, F., Rozenbaum, W., Sereni, D., et al. (2000). Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.Journal of Infectious Diseases, 182, 599–602.PubMedCrossRefGoogle Scholar
  40. Morse, E., Simon, P., Coburg, M., Hyssop, N., Greenspan, D.,; & Balson, P. (1991). Determinants of subject compliance within an experimental anti-HIV drug protocol.Social Science & Medicine, 32, 1161–1167.CrossRefGoogle Scholar
  41. Murri, R., Ammassari, A., Gallicano, K., De Luca, A., Cingolani, A., Jacobson, D., et al. (2000). Patient-reported nonadherence to HAART is related to protease inhibitor levels.Journal of Acquired Immune Deficiency Syndromes, 24, 123–128.PubMedGoogle Scholar
  42. Ostrop, N. J., Hallett, K. A., Gill, M. J. (2000). Long-term patient adherence to antiretroviral therapy.Annals of Pharmacotherapy, 34, 703–709.PubMedCrossRefGoogle Scholar
  43. Paterson,D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E.N., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomesinpatients with HIV infection.Annals of Internal Medicine, 133, 21–30.PubMedGoogle Scholar
  44. Pierret, J. (2000). Everyday life with AIDS/HIV: Surveysin the social sciences.Social Science & Medicine, 50, 1589–1598.CrossRefGoogle Scholar
  45. Pilisuk, M. (1978). Kinship, social networks, social support and health.Social Science & Medicine, 12, 273–280.Google Scholar
  46. Roca, B., Gomez, C. J., & Arnedo, A. (1999). Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: Adherence, side effects and efficacy.Journal of Infection, 39, 141–145.PubMedCrossRefGoogle Scholar
  47. Schneiderman, N., Antoni, M. H., Saab, P. G., & Ironson, G. (2001). Health psychology: Psychosocial and biobehavioral aspects of chronic disease management.Annual Review of Psychology, 52, 555–580.PubMedCrossRefGoogle Scholar
  48. Sherer, R. (1998). Adherence and antiretroviral therapyininjection drug users.The Journal of the American Medical Association, 280, 567–568.CrossRefGoogle Scholar
  49. Singh, N., Squier, C., Sivek, C., Wagener, M., Nguyen, M.,; & Yu, V. (1996). Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance.AIDS Care, 8, 261–269.PubMedCrossRefGoogle Scholar
  50. Smith, M., Rapkin, B., Morrison, A.,; & Kammerman, S. (1997). Zidovudine adherence in persons with AIDS: The relationship of patients beliefs about medication to self-termination of therapy.Journal of General Internal Medicine, 12, 216–223.PubMedGoogle Scholar
  51. Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F.,; & Moatti, J. (2002). Adherence to highly active antiretroviral therapy (HAART) inHIV-infected patients: From a predictive toa dynamic approach.Social Science & Medicine, 54, 1481–1496.CrossRefGoogle Scholar
  52. Stein, M. D., Rich, J. D., Maksad, J., Chen, M. H., Hu, P., Sobota, M., et al. (2000). Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use.American Journal of Drug & Alcohol Abuse, 26, 195–205.CrossRefGoogle Scholar
  53. Stone,V. E. (2001). Strategies for optimizing adherence tohighly active antiretroviral therapy: Lessons from research and clinical practice.Clinical Infectious Diseases, 33, 865–872.PubMedCrossRefGoogle Scholar
  54. Swindells, S., Mohr, J., Justis, J.C., Berman, S., Squier, C., Wagener, M. M., etal. (1999). Qualityoflife in patients with human immunodeficiency virus infection: Impactofsocial support, coping style and hopelessness.International Journal of STDs & AIDS, 10, 383–391.CrossRefGoogle Scholar
  55. Wagner, G., & Rabkin, J. (2000). Measuring medication adherence: Are missed doses reported more accurately than perfect adherence.AIDS Care, 12, 405–408.PubMedCrossRefGoogle Scholar
  56. Wallston, B., Alagna, S., De Vellis, B., & De Vellis, M. (1983). Social support and physical health.Health Psychology, 2, 367–391.CrossRefGoogle Scholar
  57. Wasserman, S.,; & Faust, K. (1994).Social network analysis. Cambridge, UK: Cambridge University Press.Google Scholar
  58. Wendel, C. S., Mohler, M. J., Kroesen, K., Ampel, N. M., Gifford, A. L., & Coons, S. J. (2001). Barriers to use of electronic adherence monitoring in an HIV clinic.Annals of Pharmacotherapy, 35, 1010–1015.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Behavioral Medicine 2003

Authors and Affiliations

  • M. P. Carrieri
    • 1
  • M. A. Chesney
    • 2
  • B. Spire
    • 1
  • A. Loundou
    • 1
  • A. Sobel
    • 3
  • G. Lepeu
    • 4
  • J. P. Moatti
    • 1
  1. 1.INSERM Research Unit 379MarseilleFrance
  2. 2.Center for AIDS prevention studiesUniversity of CaliforniaSan Francisco
  3. 3.CHU CréteilFrance
  4. 4.Department of HematologyH. Duffaut HospitalAvignonFrance

Personalised recommendations